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BACKGROUND: Inflammatory breast cancer (IBC) is an aggressive subtype of breast cancer with distinct molecular profiles. Gene
expression profiling previously identified sonic hedgehog (SHH) as part of a gene signature that is differentially regulated in IBC patients.
METHODS: The effects of reducing GLI1 levels on protein expression, cell proliferation, apoptosis and migration were determined by
immunoblots, MTT assay, Annexin-V/PI assay and conventional and automated cell migration assays.
RESULTS: Evaluation of a panel of breast cancer cell lines revealed elevated GLI1 expression, typically a marker for hedgehog-pathway
activation, in a triple-negative, highly invasive IBC cell line, SUM149 and its isogenic-derived counterpart rSUM149 that has acquired
resistance to ErbB1/2 targeting strategies. Downregulation of GLI1 expression in SUM149 and rSUM149 by small interfering RNA or
a small molecule GLI1 inhibitor resulted in decreased proliferation and increased apoptosis. Further, GLI1 suppression in these cell
lines significantly inhibited cell migration as assessed by a wound-healing assay compared with MCF-7, a non-invasive cell line with low
GLI1 expression. A novel high-content migration assay allowed us to quantify multiple effects of GLI1 silencing including significant
decreases in cell distance travelled and linearity of movement.
CONCLUSION: Our data reveal a role for GLI1 in IBC cell proliferation, survival and migration, which supports the feasibility of targeting
GLI1 as a novel therapeutic strategy for IBC patients.
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Inflammatory breast cancer (IBC) is one of the most lethal and
highly invasive forms of locally advanced breast cancer with a
5-year survival rate of o50%, which is significantly less than patients
with non-IBC breast cancer (85%) (Hance et al, 2005; Cristofanilli
et al, 2007). It is clear that IBC is phenotypically and molecularly
distinct from other forms of locally advanced breast cancer and IBC
tumours are particularly resistant to chemotherapeutic agents
(Charafe-Jauffret et al, 2004; Lee et al, 2004; Cristofanilli et al,
2007). Gene expression profiling has linked genes such as LIBC (loss
in IBC), Rho C, BP1 and E-cadherin to the IBC phenotype (Yamauchi
et al, 2009). A gene expression profile that distinguished between IBC
and non-IBC tumours identified sonic hedgehog (SHH) as being a
part of a three-gene signature that was differentially regulated in
IBC patients (Bieche et al, 2004). SHH, one of the three members of
the mammalian Hh family of secreted ligands (Pathi et al, 2001),
was noteworthy for being higher in patients who relapsed and had
the most aggressive form of IBC (Bieche et al, 2004). Gene
expression analysis of IBC and non-IBC tumour samples also
identified Hh-pathway overexpression in IBC samples and that this
was a predictor of the IBC phenotype (Van Laere et al, 2010).
Hh signalling in vertebrates is mediated by the downstream
zinc-finger transcription factors of the Gli protein family (Kinzler
et al, 1988), with GLI-mediated transcription being the final
step in the Hh pathway. In the absence of Hh, the receptor patched
(PTCH) inhibits Hh-pathway activity through the inhibition of
smoothened (SMO), a GPCR-like receptor that transduces the
signal for the phosphorylation and proteolysis of GLI3 into a
repressor form. GLI3 translocates to the nucleus and represses Hh
target genes. When present, Hh binds to PTCH, which releases its
inhibition of SMO. SMO is then able to transduce the signalling
cascade through the GLI1 transcriptional activator form, which
then can regulate the expression of Hh target genes including GLI1
and PTCH, making these genes markers for Hh-pathway activation
(Ingham and McMahon, 2001; Kasper et al, 2006). Hh target genes
are involved in cell proliferation, survival, differentiation, cell
cycle, stem cells and invasion (Katoh and Katoh, 2009).
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sDysregulation of the Hh-Gli pathway in cancer has been
reported and reviewed extensively (Kasper et al, 2006; Scales and
de Sauvage, 2008; Yang et al, 2009), with Hh-ligand-dependent
autocrine and paracrine (Yauch et al, 2008; Theunissen and de
Sauvage, 2009), and Hh-ligand-independent mechanisms of
activation observed (Rubin and de Sauvage, 2006). Activation of
GLI via gene amplification has been linked to tumourgenesis in a
number of tumours, including ovarian (Chen et al, 2007),
endometrial (Feng et al, 2007), prostate (Karhadkar et al, 2004)
and oesophageal (Mori et al, 2006) cancers. GLI1 contributes to the
invasiveness of pancreatic (Nagai et al, 2008; Inaguma et al, 2011),
prostate (Karhadkar et al, 2004), melanoma (Das et al, 2009) and
glioma (Wang et al, 2010a) cancers. GLI1 is overexpressed in the
majority of breast cancers (Xu et al, 2010) and a role for GLI1 in
breast cancer invasiveness has been reported (Kameda et al, 2009;
Souzaki et al, 2011). GLI1 overexpression has clinical impact and
in breast cancer correlates with poor patient prognosis (Ten Haaf
et al, 2009). A number of approaches have been taken to block
Hh-Gli signalling at different steps in the pathway including
natural products (Hosoya et al, 2008), synthetic small molecule
inhibitors such as cyclopamine derivatives (Williams et al, 2003),
blocking monoclonal antibodies (Ericson et al, 1996) and small
interfering RNA (siRNA) (Sanchez et al, 2004). More recently,
there is mounting evidence for alternative mechanisms for the
activation of Hh-Gli pathway components (Testaz et al, 2001;
Riobo and Manning, 2007; Jenkins, 2009; Chinchilla et al, 2010;
Teglund and Toftga ˚rd, 2010), with upregulation of GLI by non-
canonical pathways independent of Hh/SMO signalling reported
(Lauth and Toftgard, 2007; Fernandez-Zapico, 2008; Nolan-Stevaux
et al, 2009; Rizvi et al, 2010).
In this study, we observed that the triple-negative, Basal-like IBC
cell line SUM149, a widely used model for IBC (Ignatoski and
Ethier, 1999; Hoffmeyer et al, 2005; Dong et al, 2007; Streicher
et al, 2007; Aird et al, 2010; Wu et al, 2010; Singh et al, 2010a,b),
and rSUM149, an IBC cell line with acquired resistance to ErbB1/2
targeted agents (Aird et al, 2010), had significantly higher GLI1
expression than other cell lines tested and that targeting GLI1 by
siRNA reduced cell proliferation and migration and increased
apoptosis. We were able to quantify the effects of GLI1 silencing on
migration using a high-content imaging assay that tracked
multiple motility parameters of H2B-GFP-labelled cells. Our
findings suggest that GLI1 has a role in the proliferation, migration
and survival of the IBC cell lines.
MATERIALS AND METHODS
Cell culture and reagents
SUM149, SUM44 and SUM190 cell lines were obtained from
Asterand (Detroit, MI, USA) and SK-BR-3, MCF-7, BT474 and
MDA-MB-231 cell lines were from ATCC (Manassas, VA, USA).
Human mammary epithelial (HMEC) cells were from Duke
University Medical School. These cell lines were grown as
described previously (Aird et al, 2008). rSUM149 and rSUM190
were grown as described (Aird et al, 2010). Sonic hedgehog (ShhN)
recombinant protein was from R&D Systems (Minneapolis, MN,
USA). The hybridoma expressing 5E1 monoclonal antibody
developed by Thomas Jessell (Ericson et al, 1996) was obtained
from the Developmental Studies Hybridoma Bank developed
under the auspices of the NICHD and maintained by the University
of Iowa, Department of Biology (Iowa City, IA, USA). The activity
of the ShhN ligand and ability of 5E1 to block this activity was
confirmed in the standard C3H10T1/2 differentiation assay for Hh
activity (Pepinsky et al, 1998; Williams et al, 1999; Wang et al,
2000). The ShhN ligand had an EC50 value of 2mgml
–1in this assay
(Supplementary Figure 1A) comparable to previously reported
values (Williams et al, 1999; Pathi et al, 2001) and 5E1 was effective
at blocking this activity compared with control Ab (Supplementary
Figure 1B).
3-Keto-N-(aminoethyl-aminocaproyl-dihydrocinnamoyl)-cyclo-
pamine (KAAD-cyc), tomatidine and GANT58 were from
Calbiochem (La Jolla, CA, USA) and dissolved in DMSO at 2mM
stock concentration.
Real-time PCR
Total RNA was extracted from cells using an RNA extraction
kit (Ambion, Austin, TX, USA). RNA (0.5–1mg) was converted
into cDNA using the high-capacity cDNA RT–PCR kit
(Applied Biosystems, Carlsbad, CA, USA). Quantitative real-time
PCR (qRT–PCR) analyses were carried out in an ABI Prism
Fast 7500 system (Applied Biosystems). Gene expression for
GLI1 (Hs00171790_m1), SHH (Hs00179843_ml), E-cadherin
(Hs00170423_ml) and Snail (Hs00195591_ml) were analysed using
the indicated pre-designed Taqman gene expression assays
(Applied Biosystems). A b-actin primer set (Ambion) was used
as an internal control. Folds difference (2
 DDCT) were calculated as
described previously (Aird et al, 2008) and represent changes
normalised to a reference HMEC cell line.
Immunoblot analysis
Cells were lysed in 50mM Tris–HCl, pH 8.0, 150mM sodium
chloride, 1.0% Igepal CA-630 (NP-40), 0.5% sodium deoxycholate
and 0.1% sodium dodecyl sulphate supplemented with a protease
inhibitor cocktail (Sigma, St Louis, MO, USA). Cell lysates were
separated by SDS–PAGE and immunoblot analysis was carried out
as previously described (Aird et al, 2008, 2010). Membranes were
probed with a primary antibody against GLI1 (R&D Systems) at
1:10000 dilution overnight at 41C. Probing with other primary
antibodies for X-linked inhibitor of apoptosis protein (XIAP) and
procaspase 9, and appropriate HRP-conjugated secondary anti-
bodies was carried out as previously described (Aird et al, 2008).
Bands were visualised using SuperSignal West Dura Extended
Duration Substrate (Pierce, Rockford, IL, USA). As a loading
control, membranes were stripped and reprobed with a primary
antibody against b-actin (1:50000; Sigma).
RNA interference
Silencer pre-designed siRNA specific for GLI1 (siRNA ID number
115642), Silencer pre-designed siRNA specific for monoamine
oxidase (Maob) (siRNA ID number 49300) and Silencer Negative
Control siRNA were from Ambion. An alternative GLI1 siRNA
was Dharmacon siGenome SMART pool Human GLI1 (Cat.
# M-003896; Thermo Scientific, Lafayette, CO, USA). Cells were
transfected according to the manufacturer’s instructions either
with the GLI1-specific siRNA or with the control siRNAs at 100nM
using lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA). Down-
regulation of GLI1 expression was measured 72h after transfection
by RT–PCR and immunoblot analysis. Lipofectamine alone was
used as a control in all siRNA experiments. In some experiments,
cells were viewed by phase light microscopy using an Olympus
IX51 inverted microscope at a  100 magnification and cells were
visualised using the NIS-Elements BR (Nikon, Melville, NY, USA)
imaging software. Pictures were taken with a Nikon Digital Sight
Camera.
Cell proliferation
Cell proliferation was measured as described previously (Aird et al,
2008). Cells were seeded at a density of 2000 cells per well in a
96-well plate and cultured for 72h. Culture medium was aspirated
and replaced with fresh media on the day of treatment. After
treatment with agents, culture media was aspirated, and 5mgml
–1
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s3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide
(MTT; Sigma) was added. Cells were incubated at 371C for 4h to
allow formation of the coloured formazan product. The reagent
was aspirated and 100ml of DMSO was added in each well. Plates
were incubated for a further 2h and then absorbance (550nm) was
measured using a SpectraMax plate reader (Molecular Devices,
Sunnyvale, CA, USA). Triplicate wells were used for each
treatment.
Cell viability
Cell viability was determined by trypan blue exclusion assay. Cells
were trypsinized and resuspended in medium to achieve a
homogeneous mixture. An aliquot of cell suspension was mixed
with an equal volume of 0.4% trypan blue solution (Sigma). Cells
were counted using a Vi-Cell cell viability analyzer (Beckman
Coulter, Brea, CA, USA).
Apoptosis assay
Cells were stained for Annexin-V and PI using the Annexin-V-
Biotin Kit (Beckman Coulter) as described previously (Aird et al,
2010). At least 25000 events were collected on a FACSCalibur flow
cytometer (BD Biosciences, San Jose, CA, USA) and analysed using
Cellquest software.
Wound-healing assay
Cells were grown to confluence in six-well plates and then
scratched with a p200 pipette tip to create a gap. The wells were
rinsed with PBS to remove displaced cells and fresh media was
added. For siRNA experiments, transfection of cells either with
100nM of GLI1-specific siRNA or with 100nM of the control
siRNAs was performed as described above and 48h after
transfection, the wells were scratched. Cells were visualised using
an Olympus IX51 inverted microscope. Brightfield images taken at
 40 and  100 magnification over 24h were analysed using the
open-source CellProfiler software (Carpenter et al, 2006) to
calculate the area of wound occupied by cells at 0 and 24h. The
percentage of wound occupied was calculated by dividing the non-
recovered area at 24h by the initial wound area at 0h and
subtracting this value as a percentage from 100%.
Transduction with histone 2B-green fluorescent protein
SUM149 were fluorescently labelled using the BacMam-based
Cellular Lights histone 2B-green fluorescent protein (H2B-GFP)
reagent (Invitrogen; Cat. No 10128). SUM149 cells were seeded at
200000 cells in a 75cm
2 T-flask and grown overnight as described
above. Media was aspirated and the Cellular Lights transduction
reagent was added. Cells were incubated in the dark for 4h at room
temperature. The transduction reagent was replaced with an
enhancer reagent for 2h and then the transduced SUM149 cells
were incubated in complete media for 18h at 371C, 5% CO2.
High-content migration assay
The H2B-GFP-labelled SUM149 cells were seeded at 10000 cells per
well in black 96-well clear bottom plates (Costar, Acton, MA,
USA) and allowed to attach as described above. The cell plate was
mechanically scratched using a 96-well head with p200 tips on a
Biomek NX workstation (Beckman Coulter). For siRNA experi-
ments, SUM149 cells were seeded at 3000 cells per well and
incubated for 24h before transfection either with 100nM of GLI1-
specific siRNA or with 100nM of the negative control siRNA.
Transfection was carried out as described above and 48h after
transfection, the wells were scratched with p200 tips as above. Cell
plates were then imaged on a BD pathway 855 high-content
imaging system (BD Biosciences) for live-cell tracking studies with
environmental control (371C, 5% CO2). A standard GFP filter set
was used (Ex 485/20, Em 530/15) for fluorescent imaging using a
Nipkow spinning-disc confocal unit to minimise photoexposure/
toxicity. Tiff images (16-bit) were collected every 20min for 24h
for each well and the data were compiled in an uncompressed avi
format to yield one video file per well. The open-source
CellProfiler software (Carpenter et al, 2006) was used for
automated motility analysis. In brief, cells were identified
automatically by segmenting the GFP/nuclear image and each
individual cell was tracked using the TrackObjects module in
CellProfiler. X, Y trajectories were tabulated for each cell observed
in the time series and unique object numbers were assigned to
cells. The following outputs were calculated in CellProfiler
(Carpenter et al, 2006): cell linearity, a measure of how linear
the object trajectory is during the object lifetime (calculated as
(distance from initial to final location)/(integrated object distance)
with value in range of [0,1]); average distance travelled, distance
travelled by the object from the previous frame to the current
frame (calculated as the magnitude of the distance travelled vector)
and integrated distance travelled (total distance travelled by the
object during the lifetime of the object) using the X,Y trajectories.
Statistical analysis
Statistical analyses were performed using Graphpad InStat
Student’s two-tailed t-test. Differences were considered significant
at Po0.05.
RESULTS
The GLI1 transcription factor is highly expressed in the
IBC cell lines SUM149 and rSUM149
As there is a growing body of evidence that shows that the
downstream transcription factor GLI1 is an essential marker for
Hh-pathway activation (Pasca di Magliano and Hebrok, 2003;
Kasper et al, 2006), that sonic hedgehog (SHH) has been identified
as part of a gene signature differentially regulated in IBC patients
with an aggressive phenotype (Bieche et al, 2004) and that
hyperactivation of the Hh pathway is part of an IBC gene signature
(Van Laere et al, 2010), comparative gene expression of GLI1 was
characterised in a panel of IBC and non-IBC breast cancer (MCF-7,
SK-BR-3, BT474 and MDA-MB-231) cell lines. The IBC panel
included the two well-established lines: SUM149 (activated ErbB1,
ER/PR negative, ErbB2 low) and SUM190 (ErbB2 overexpressing,
ER/PR negative), both of which were originally derived from
primary IBC tumours, SUM44 (ErbB2 low, ER/PR positive) cell line
derived from the pleural effusion of a patient with luminal breast
cancer (Forozan et al, 1999), and two isogenic clonal derivatives of
the SUM149 and SUM190 that have gained resistance to ErbB1/2
targeting agents such as lapatinib termed rSUM149 and rSUM190
(Aird et al, 2010). Phenotypic status of these cell lines is from
published studies (Neve et al, 2006; Willmarth and Ethier, 2006;
Kao et al, 2009; Aird et al, 2010; Wang et al, 2010b).
Notably, qRT–PCR analysis of basal GLI1 expression revealed
that IBC cell lines, SUM149 and rSUM149, had a 19.4-fold and
28.7-fold higher level of GLI1 expression, respectively, relative to
HMEC, and GLI1 expression was significantly higher compared
with the other non-IBC cells tested (Figure 1A). The low expression
levels of GLI1 mRNA observed in the HMEC and MCF-7 cells are
consistent with previous reports for these cell lines (Kubo et al,
2004; Mukherjee et al, 2006; Zhang et al, 2008). GLI1 protein levels,
as assessed by immunoblot analysis, reflected GLI1 mRNA levels in
that GLI1 protein was expressed at higher levels in SUM149
(two-fold) and rSUM149 (1.5-fold) compared with MCF-7 cells and
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shigher than in the other IBC cell lines tested, SUM190 and
rSUM190 (data not shown).
GLI1 expression in SUM149 and rSUM149 cells is
Hh-ligand and SMO independent
Since GLI1 mRNA levels are reliable indicators of Hh-pathway
activation (Kasper et al, 2006), our data suggest that the Hh
pathway may be constitutively active in SUM149 and rSUM149
cells, resulting in the observed high expression levels of GLI1. Hh-
pathway activation generally proceeds through one of two main
mechanisms: either Hh-ligand-dependent or Hh-ligand-indepen-
dent (Rubin and de Sauvage, 2006). We first investigated whether
GLI1 activation in SUM149 and rSUM149 cells occurs through a
Hh-ligand-dependent mechanism by analysing whether these cells
express sonic hedgehog (SHH) ligand. qRT–PCR analysis of basal
SHH ligand expression revealed an B3-fold and B5-fold higher
level of SHH expression in SUM149 and rSUM149 cells,
respectively, compared with HMEC and the other IBC and non-
IBC cells tested (Figure 1B).
We next tested the responsiveness of these IBC cell lines to
exogenous ShhN (active N-terminal form of Shh) ligand. Using
RT–PCR of GLI1 mRNA levels as a sensitive readout of
Hh-pathway activity, we observed that the addition of exogenous
recombinant ShhN ligand to SUM149 or rSUM149 cells compared
with media alone did not increase the expression of GLI1
(Figure 2A, left panel).
To further investigate any role for autocrine Hh-ligand-
dependent growth, SUM149 and rSUM149 cells were cultured
with a pan-Hh neutralising monoclonal antibody (5E1) (Ericson
et al, 1996). 5E1 did not significantly reduce the expression of GLI1
mRNA in SUM149 or rSUM149 cells treated with the anti-Hh mAb
compared with an isotype control (Figure 2A, right panel). In
addition, neither the addition of ShhN protein nor 5E1 Ab had any
effect on GLI1 protein levels compared with controls as assessed
by immunoblot (Figure 2B) and did not affect SUM149 cell
proliferation (Figure 2C). These results suggest that although SHH
is expressed in SUM149 and rSUM149 cells, GLI1 activation does
not appear to be Hh-ligand-dependent.
Hh-ligand-independent activation of GLI1 expression via loss of
PTCH or oncogenic mutations in SMO have been reported for a
number of cancers and pharmacological inhibition with SMO-
directed inhibitors shown to block Hh signalling and cell
proliferation (Taipale et al, 2000; Chen et al, 2002). We tested
the effects of the SMO inhibitor KAAD-cyclopamine (KAAD-cyc)
compared with an inactive analogue (tomatidine) on GLI1 mRNA
levels and observed that concentrations of 10mM or greater of
KAAD-cyc were required to reduce GLI1 levels in SUM149 or
rSUM149 cells (Figure 2D). A comparable response was observed
when assessing the effects of KAAD-cyc on SUM149 (Figure 2E)
and rSUM149 (data not shown) cell proliferation as measured by
MTT assay. Using the same stock solution of KAAD-cyc in the Hh
responsive C3H10T1/2 cell assay (Williams et al, 1999), we
determined IC50 values of B10nM for KAAD-cyclopamine (data
not shown) and comparable values have been reported in other Hh
reporter cell assays (Taipale et al, 2000). Hence, the micromolar
concentration of KAAD-cyc required to block SUM149 cell
proliferation here is much higher than that typically required to
inhibit Hh-pathway activity, suggesting a SMO-independent off-
target inhibitory effect as has been suggested for its in vitro growth
inhibitory effects on other cancer cell lines (Yauch et al, 2008;
Zhang et al, 2008). As of yet, no other non-SMO targets have been
identified for KAAD-cyclopamine (Zhang et al, 2008).
Downregulation of GLI1 expression in SUM149 by either
siRNA or a GLI-directed inhibitor results in decreased
cell growth
Since SUM149 and rSUM149 cells express high levels of GLI1 but
these high levels appear to be Hh-ligand and SMO independent, we
evaluated the effects of direct silencing of GLI1 expression on cell
behaviour by transfecting GLI1 siRNA and control siRNA for 72h.
Immunoblot analysis in Figure 3A showed decreased GLI1 protein
expression by 93% at 100nM GLI1 siRNA compared with control
siRNA (P-value o0.05). Further, a significant decrease (Po0.05)
in cell proliferation was observed in GLI1 siRNA-treated cells
(46–50% decrease compared with controls, Figure 3B) as assessed
by the MTT assay. Phase-contrast analysis showed a higher degree
of nucleation in the SUM149 cells transfected with GLI1 siRNA
compared with the vehicle (lipofectamine only) and control
siRNA-transfected cells (Figure 3C).
In addition, we compared a recently described direct inhibitor of
GLI1 transcription (GANT58) that acts downstream of Hh
signalling (Lauth et al, 2007). Immunoblot analysis of SUM149
cells after treatment with GANT58 for 72h showed GLI1 protein
levels decreased at 20mM compared with untreated cells
(Figure 3D, left panel) or cells treated with 20mM tomatidine
(Figure 3D, right panel). Characterisation of cell proliferation
using an MTT assay revealed that proliferation of SUM149 cells
was significantly suppressed at 20mM GANT58 (54% proliferation
vs 80% for control) (Figure 3E). GANT58 was effective on SUM149
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Figure 1 GLI1 and SHH expression in IBC and non-IBC cell lines. Total
RNA (1mg) was reverse transcribed and assessed for expression of GLI1
(A) and SHH (B) mRNA using real-time PCR. b-Actin was used as an
internal control. Data indicate values performed in triplicate and the fold
difference relative to HMEC.
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scells at concentrations comparable to those we determined in the
C3H10T1/2 assay (data not shown) and to published IC50 values of
5mM for GANT58 in GLI reporter assays (Lauth et al, 2007),
suggesting that it is acting on GLI.
As silencing with siRNA was a more effective method at
reducing GLI1 levels in SUM149 cells compared with the small
molecule GANT58, subsequent studies were done with siRNA.
GLI1 silencing induces apoptosis
To determine if the observed decrease in proliferation seen
with GLI1 silencing was due to an increase in apoptosis,
Annexin-V staining was performed. Both early apoptotic
cells (Annexin-V positive and PI negative) and late apoptotic cells
(Annexin-V positive and PI positive) were counted. Data in
Figure 4A demonstrate that after 72h, GLI1 siRNA treated SUM149
cells had a 3.2-fold increase in Annexin-V-positive cells (58%) over
the control siRNA-transfected cells (18%). To further understand
the mechanism of the observed cell death, immunoblot analysis
was conducted to examine the effect of GLI1 knockdown on the
expression of key apoptotic signalling proteins. Immunoblot
analysis (Figure 4B) shows that at 72h, GLI1 siRNA dramatically
decreased the expression of procaspase 9 compared with control
siRNA. This corresponded with a significant decrease in expres-
sion of XIAP (Figure 4B), one of the most potent caspase inhibitors
and anti-apoptotic proteins that has recently been reported to be a
key determinant in apoptotic dysregulation in IBC (Aird et al,
2008, 2010).
In light of the reported high levels of E-cadherin associated with
the IBC invasive phenotype and in SUM149 cells (Kleer et al, 2001;
Colpaert et al, 2003; Hoffmeyer et al, 2005; Dong et al, 2007), we
were interested to see what affect GLI1 silencing would have on E-
cadherin expression in SUM149. A mechanistic link between GLI1
and E-cadherin occurs as part of epithelial transformation via the
transcription factor Snail (Li et al, 2006, 2007). We found that GLI1
silencing in SUM149 cells reduced E-cadherin levels as assessed by
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Figure 2 GLI1 expression in SUM149 cells is Hh-ligand and SMO independent. (A) RT–PCR analysis of GLI1 mRNA expression in SUM149 and
rSUM149 cells treated for 72h with media or 2mgml
–1recombinant ShhN (left panel) or with 100mgml
–15E1 antibody or 100mgml
–1isotype control
antibody (right panel). b-Actin was used as an internal control. (B) Immunoblot analysis for GLI1 protein expression in SUM149 cells (7 10
4 cells per well
in six-well plates) treated for 72h with media or ShhN (left panel) or with 5E1 antibody or control antibody (right panel). Membranes were stripped and
reprobed for b-actin as an internal control for equal loading. (C) Cell proliferation was determined by MTT assay in SUM149 cells (2000cells per well in 96-
well plates) treated for 72h with media or ShhN (left panel) or with 5E1 antibody or control antibody (right panel). (D) RT–PCR analysis of GLI1 mRNA
expression in SUM149 (upper panel) and rSUM149 (lower panel) cells treated for 72h with the indicated concentrations of KAAD-cyclopamine (KAAD-
cyc) or its inactive analogue tomatidine. b-Actin was used as an internal control. (E) Cell proliferation was determined by MTT assay in SUM149 cells
(2000cells per well) plated in 96-well plates following treatment for 72h with the indicated concentrations of KAAD-cyc and its inactive analogue
tomatidine.
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sqRT–PCR compared with controls (Figure 4C) but did not affect
Snail levels (Figure 4D).
GLI1 silencing impairs IBC cell migration
Since targeting GLI1 inhibited cell proliferation, increased
apoptosis and decreased E-cadherin that has been identified to
be maintained in aggressive IBC phenotype, we investigated the
effect of GLI1 silencing on the migration potential of SUM149 and
rSUM149 cells using an in vitro wound-healing assay. The in vitro
wound-healing assay is frequently used as a simple assay to mimic
and assess migration (Liang et al, 2007) and has been used
previously to assess the invasiveness of SUM149 cells (Hoffmeyer
et al, 2005). In this assay, an artificial wound is created by
scratching a confluent monolayer of cells and the ability of the cells
to move into and close the wound is thought to predict their
migration ability in vivo (Liang et al, 2007).
In our study, cells were seeded into six-well plates, grown to
confluence and scratched with a p200 pipette tip to create a wound.
Migration of cells into the wound was assessed by taking phase-
contrast images at time points over 24h. MCF-7 cells, a breast
cancer cell line with low invasive potential (Neve et al, 2006),
showed little migration in the wound-healing assay over 24h
(Figure 5A). In contrast, SUM149 (Figure 5A, vehicle) and
rSUM149 cells (Figure 5B, vehicle) migrate into and close the
‘wound’ over the same 24h time period consistent with previous
observations that SUM149 cells are more invasive than MCF-7 cells
(Neve et al, 2006).
We next tested the effect of silencing GLI1 expression
in SUM149 and rSUM149 cells on their migratory phenotype.
Cells were first transfected with either GLI1 siRNA, siRNA to
an unrelated target Maob or control siRNA for 48h and then
scratched as before. Compared with both vehicle-treated
(lipofectamine alone), control and Maob siRNA-treated cells,
silencing of GLI1 in SUM149 (Figure 5A) and rSUM149 (Figure 5B)
cells resulted in a significant reduction in migration ability. Cell
viability was also assessed after siRNA treatment and subsequent
wounding for 24h, and viability was only marginally decreased by
B20% in GLI1 siRNA-treated SUM149 cells compared with vehicle
and control siRNA treatment. Comparable values were observed
for rSUM149 cells (data not shown).
To quantify SUM149 cell motility in our scratch assays, the
brightfield images taken at  40 magnification shown in Figures
5A and B were analysed using the open-source CellProfiler
software (Carpenter et al, 2006) to calculate the area occupied by
cells at 0 and 24h. The percentage of wound area recovered was
calculated by dividing the non-recovered area at 24h by the initial
wound area at 0h. This analysis (Figure 5C) showed that 24h after
wounding, the vehicle and control siRNA-treated SUM149 cells
had occupied 68 and 75%, respectively, of the wound while the
GLI1 siRNA SUM149 cells had occupied only B5%, a value
comparable to that determined for MCF-7. Comparable data were
obtained for rSUM149 cells (Figure 5C). These results suggest that
silencing GLI1 in SUM149 and rSUM149 cells has a significant
effect on cell motility. We also tested the effect of GANT58 (5, 10
and 20mM) on SUM149 motility and observed a modest reduction
in migration at the highest dose compared with controls (data
not shown).
High-content imaging analysis of H2B-GFP-tagged
SUM149 cells shows that silencing GLI1 reduces cell
distance travelled and linearity of cell motility
High-content automated microscopy (HCAM) was used to
generate quantitative information from the wound-healing assay,
and to extract other critical parameters defining migration
1.5
Vehicle Control siRNA GLI1 siRNA
1.0
V
e
h
i
c
l
e
G
L
I
1
 
s
i
R
N
A
C
o
n
t
r
o
l
 
s
i
R
N
A
*
GLI1
0.5
Actin
0
Control siRNA
GLI1 siRNA
C
e
l
l
u
l
a
r
 
p
r
o
l
i
f
e
r
a
t
i
o
n
 
r
e
l
a
t
i
v
e
t
o
 
v
e
h
i
c
l
e
 
(
A
b
s
 
5
5
0
 
n
m
)
Control GANT58
100
80
[GANT58] (M) [Tomatidine] (M)
20 V
60
20 10
GLI1
V
40
Actin
C
e
l
l
u
l
a
r
 
p
r
o
l
i
f
e
r
a
t
i
o
n
r
e
l
a
t
i
v
e
 
t
o
 
v
e
h
i
c
l
e
 
(
%
)
20
0
10 20 5
[Compound] (M)
Figure 3 Reducing GLI1 expression in SUM149 cells by either siRNA knockdown or small molecule treatment results in decreased proliferation. SUM149
cells (7 10
4 cells per well in six-well plates) were transfected with 100nM of GLI1 siRNA or control siRNA for 72h. Vehicle is lipofectamine alone.
(A) Immunoblot analysis of GLI1 protein expression. The blot was stripped and reprobed for b-actin as an internal control for equal loading. (B) Cell
proliferation was measured after 72h by MTT assay. Experiments were performed in triplicate, P-value o0.05. (C) SUM149 cells were examined for
morphology under phase light microscopy using an Olympus IX51 inverted microscope at a  100 magnification. Bar¼100mm. (D) Immunoblot for GLI1
protein expression in SUM149 cells treated for 72h with indicated concentrations of GANT58 (left panel) or tomatidine (right panel). b-Actin was used as
an internal control for equal loading. (E) Cell proliferation was measured by MTT for SUM149 cells following treatment for 72h with indicated
concentrations of GANT58 or tomatidine as a control. Data are shown as relative to control (%).
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sbehaviour. High-content automated microscopy was conducted
using the BD pathway 855 imaging system, which is multi-well
plate compatible and equipped with an environmentally controlled
chamber (CO2 and temperature), allowing live-cell imaging over
many hours. For wounding, cells were seeded in 96-well plates
and after reaching confluence scratched simultaneously using p200
tips on a 96-well head configured on a Biomek NX robotics
workstation.
SUM149 cells were transduced with baculoviral particles
expressing H2B-GFP to label the nuclei and Figure 6A (left panel)
reveals the live-cell tracking as imaged on the BD Imaging
workstation. The advantages of H2B-GFP labelling are that this
reporter system does not affect cell viability (Quaranta et al, 2009)
and cells are brightly labelled by tagging nuclei compared with
diffuse labelling as for cytoplasmic markers. As part of our
preliminary high-content studies, we observed that dyes such as
MitoTracker Red and CellTracker were not suitable for tracking
purposes as SUM149 cells treated with these dyes exhibited no
motility (data not shown). Further, extended live-cell fluorescent
imaging can cause significant phototoxicity so we chose to limit
overall light exposure by using a spinning-disc confocal unit,
rather than widefield. Although exposure times increase, the
spinning disc reduces the field of illumination from the entire well
to pinhole sized, dramatically reducing the overall photoexposure
per cell.
High-content imaging of H2B-GFP SUM149 cells after GLI1
silencing allowed us to measure effects on multiple motility
parameters through careful feature extraction from X,Y trajec-
tories. SUM149 cells were seeded in 96-well plates and after
reaching confluence, silenced with GLI1 siRNA and mechanically
scratched as described above. Migration of the cells into the wound
was assessed over 24h and image data were filtered, cells
segmented and tracked using both NIH ImageJ and CellProfiler
(Figure 6A, right panel) for each well per condition. The live-cell
tracking algorithm for the vehicle control (lipofectamine only) and
negative control siRNA showed similar motility, whereas the
motility of GLI1-silenced SUM149 cells was low. Many features of
each cellular trajectory were tabulated and compared for each
experimental condition. Representative trajectories for SUM149
treated with either the negative control siRNA or GLI1 siRNA
(Figure 6B) shows that the SUM149 cells with silenced GLI1 have
reduced translational progress. X, Y trajectories were tabulated for
each cell observed in the time series and unique object numbers
were assigned to cells. We extracted numerous features from the X,
Y trajectories and found significant changes in the integrated
distance travelled, and the calculated linearity of the trajectory. A
population scatterplot (Figure 6C) shows distance travelled vs
linearity for individual cells from both the GLI1 knockdown (red)
and the negative control siRNA-treated SUM149 cells (blue).
Although there is some overlap between the two cell sets with a
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Figure 4 GLI1 siRNA knockdown in SUM149 cells results in increased apoptosis and decreased levels of anti-apoptotic proteins. (A) Apoptosis was
determined by the Annexin-V/PI assay for SUM149 cells (7 10
4cells per well) plated in six-well plates and transfected with 100nM of control or GLI1
siRNA for 72h. (B) Immunoblots of procaspase 9, XIAP and GLI1 protein expression in SUM149 cells (7 10
4 cells in six-well plates) transfected with
100nM of GLI1 siRNA or control siRNA for 72h. The blots were stripped and reprobed for b-actin as an internal control for equal loading. E-cadherin (C)
and Snail (D) mRNA expression levels were assessed by RT–PCR in SUM149 cells transfected with 100nM of GLI1 siRNA or 100nM control siRNA for
72h. Vehicle is liptofectamine alone treated cells. b-Actin was used as an internal control and data indicate values performed in triplicate and the fold
difference relative to b-actin.
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ssmall number of GLI1 siRNA cells still showing high motility, there
is a dramatic difference between the control and siRNA-treated
SUM149 cells. Plotting these data show a significant decrease in
both distance travelled (Figure 6D, left panel) and linearity
(Figure 6D, right panel) in the GLI1 knockdown compared with
control siRNA-treated SUM149 cells, suggesting a link between
GLI1 expression and cell motility.
DISCUSSION
We report herein a role for the transcription factor GLI1 in the
growth, survival and migration of two IBC cell lines, SUM149 cells,
a triple-negative IBC cell line with activated EGFR, isolated from a
primary tumour of an IBC patient (Forozan et al, 1999; Ignatoski
and Ethier, 1999) and rSUM149, an isogenic cell line with acquired
resistance to ErbB1/2 inhibitors (Aird et al, 2010). Both SUM149
and rSUM149 expressed significantly higher levels of GLI1
compared with other IBC cell lines SUM190 and rSUM190, non-
IBC cell lines MCF-7, SK-BR-3, BT474 MDA-MB-231 and normal
mammary epithelial cells evaluated in this study. To validate the
role of elevated GLI1 expression in SUM149 and rSUM149 cell
growth, we investigated direct blocking of GLI1 expression by RNA
interference. The decrease in cell proliferation and increase in
apoptosis in SUM149 cells treated with GLI1 siRNA corresponded
with decreased levels of the most potent anti-apoptotic proteins
XIAP and its target procaspase 9. The role of apoptotic
dysregulation as mediated by the inhibitor of apoptosis protein
XIAP has been recently reported by our group as a mechanism of
therapeutic resistance to apoptosis in IBC cells (Aird et al, 2008,
2010). Further, herein we observed that the migration ability of the
SUM149 and rSUM149 cells when GLI1 was silenced was
dramatically reduced compared with control-transfected cells as
assessed in both a conventional scratch assay and a novel
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Figure 5 Silencing GLI1 expression impairs motility of SUM149 and rSUM149 cells. Cells were grown to confluence in six-well plates and scratched with a
sterile pipette tip. Closure of the wound was monitored over 24h. In vitro wound-healing assay on SUM149 (A) and rSUM149 cells (B) treated with vehicle
(lipofectamine alone), control siRNA, Maob siRNA and GLI1 siRNA. Images were taken at  40 magnification over 24h. Wound-healing assay for MCF-7 is
shown as a control. Immunoblots are shown to confirm significant knockdown of GLI1 protein only in cells treated with siRNA to GLI1.( C) Images from
(A and B) were analysed using CellProfiler software to calculate the area occupied by cells at 0 and 24h. The percentage of wound occupied was calculated
by dividing the non-recovered area at 24h by the initial wound area at 0h and subtracting this value as a percent from 100%.
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The present study, therefore suggests that upregulation of GLI1 is
important for survival and migration in these IBC cells.
The only previous reports connecting the Hh-Gli pathway with
IBC was a gene array study linking a three-gene signature
including the Sonic hedgehog (SHH) gene with poor outcome in
IBC patients (Bieche et al, 2004), and another gene expression
study demonstrating that IBC is characterised by Hh-pathway
hyperactivation (Van Laere et al, 2010). GLI1 has been reported
extensively as a universal marker for Hh-pathway activation.
Elevated GLI1 expression and its role in a number of cancers has
been widely reported, including a recent study that the conditional
expression of GLI1 in mouse mammary glands results in
mammary tumours (Fiaschi et al, 2009). Aberrant activation of
GLI1 expression might arise from a number of possible mechan-
isms with both canonical Hh-pathway-dependent (Rubin and de
Sauvage, 2006; Yauch et al, 2008) and non-canonical Hh-
independent (Lauth and Toftgard, 2007; Jenkins, 2009) activation
of GLI1 reported for different cancers. We observed that neither
the addition of exogenous Shh ligand nor a blocking Hh antibody
was able to affect the growth or levels of GLI1 in SUM149 or
rSUM149 IBC cell lines. Lack of responsiveness to added Hh-ligand
is expected considering the very low levels of SMO expression
observed in SUM149 cells (data not shown). Similarly, most non-
IBC breast cancer cell lines do not respond to exogenous ShhN to
activate Hh signalling or increase GLI (Zhang et al, 2008). Taken
together with our observation of the high concentration of KAAD-
cyc required to elicit growth effects, the present study suggests that
in SUM149 cells GLI1 activation is not Hh-ligand or SMO
dependent.
The data from GLI1 siRNA silencing studies suggest a more
effective approach to targeting SUM149 cells would be by directly
inhibiting GLI1 transcription. To further probe the molecular basis
for GLI1 activation in SUM149 cells, we tested the effects of a direct
GLI inhibitor, GANT58, which has been reported to block GLI1-
induced transcription in vitro and prevent additional tumour
growth in xenograft tumour models (Lauth et al, 2007). We
observed that GANT58 also reduced cell proliferation of SUM149
cells and reduced GLI1 protein expression. Although its mechan-
ism of action is unclear, GANT58 has been reported to act on
nuclear localised GLI (Lauth et al, 2007) and it appears to be highly
selective for GLI as it has no effect on other signalling pathways
such as TNF/NFkB and Ras/MAPK or on protein folding or nuclear
transport (Lauth et al, 2007). Targeting GLI1 in the clinic with
siRNA is not currently feasible and the availability of more potent
GLI inhibitors would be beneficial. Other GLI1 inhibitors have
been recently described (Hosoya et al, 2008; Hyman et al, 2009;
Mahindroo et al, 2009) that target multiple steps in GLI regulation,
although with micromolar potencies comparable to the GANT
compound.
IBC is an aggressive clinical subtype of breast cancer that is an
extremely invasive and metastatic disease (Cristofanilli et al, 2007)
that falls into two major subtypes; Basal-like or ErbB2 over-
expressing (Van Laere et al, 2007). The cellular models that were
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Figure 6 High-content imaging and migration analysis of SUM149 H2B-GFP cells demonstrate that cell linearity and distance travelled are decreased in
SUM149 cells with GLI1 attenuated. (A) (Left panel) SUM149 cells transduced with BacMam H2B-GFP viral particles. Image was taken with a  10 Olympus
objective. (Right panel) Automated cell detection was performed using CellProfiler by segmenting each nucleus using the Otsu image segmentation.
Segmented nuclei are shown by colour (right image). (B) Cell plates were imaged on a BD pathway 855 high-content imaging system with Nikpow spinning
disc for live-cell fluorescent imaging. Tiff images (16-bit) were collected every 20min for 24h for each well and the data were compiled in an uncompressed
avi format to yield one video file per well. CellProfiler software was used for video tracking using the minimum displacement method in the TrackObjects
module. Representative trajectories for SUM149 cells treated with a negative control siRNA or GLI1 siRNA are shown. (C) X, Y trajectories were tabulated
for each cell observed in the time series and unique object numbers were assigned to cells. Population scatterplot showing distance travelled vs linearity for
cells treated with GLI1 siRNA or negative control siRNA. (D) (Left panel) Integrated distance travelled for the negative control siRNA and GLI1 siRNA-
treated samples. (Right panel) Average linearity for the negative control siRNA and GLI1 siRNA-treated samples.
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models available; SUM149, an ErbB1 activated, triple-negative
(ErbB2-, ER- and PR-) cell line and SUM190, an ErbB2 over-
expressed, ER- cell line, both of which have been derived from
primary IBC tumours (Forozan et al, 1999). Both these cell lines
are sensitive to ErbB1/2 targeting agents (Aird et al, 2008, 2010).
SUM149 cells were generated from an aggressive IBC (Forozan
et al, 1999) and have been characterised as a Basal B subtype of
breast cancer cell (Neve et al, 2006), which is frequently more
aggressive and invasive than other breast cancer cell types. As GLI1
has been observed to promote cell migration and invasion in other
cancer cell types (Das et al, 2009; Lo et al, 2009), including non-
IBC breast cancer cell lines (Kameda et al, 2009; Souzaki et al,
2011), we were interested to determine if it has a role in the
invasive potential of SUM149 and rSUM149 cells. Further, IBC is
unusual in that it is an aggressive type of breast cancer that
maintains strong E-cadherin expression (Kleer et al, 2001; Colpaert
et al, 2003; Dong et al, 2007). We wanted to investigate whether the
high levels of GLI1 in SUM149 cells have a role in its unique
migratory phenotype. Silencing of GLI1 reduced the level of E-
cadherin but not of Snail, a transcription factor that promotes
epithelial–mesenchymal transitions and is a key target of GLI1 (Li
et al, 2006, 2007). The molecular mechanisms linking GLI1
expression to E-cadherin and the invasive phenotype of SUM149
warrants further investigation.
In our study, we used the in vitro wound-healing assay as a
measure of migration and found that silencing of GLI1 in SUM149
and rSUM149 cells dramatically reduces cell migration over 24h.
From a previous study looking at the invasive potential of 30 breast
cancer cell lines across subtypes, SUM149 falls within the Basal B
subtype of highly invasive cells as assessed in 24h Boyden
chamber assays (Neve et al, 2006). In contrast, other reports have
suggested a less migratory phenotype for SUM149 (Nieman et al,
1999; Hoffmeyer et al, 2005) and that migration occurs by a passive
dissemination process (Hoffmeyer et al, 2005). These differences
may be attributable to differences in format and time assessed as
one report used the wound-healing assay over a shorter (7.5h)
time frame (Hoffmeyer et al, 2005).
Studies in non-IBC breast cancer cell lines have suggested a link
between ER status, GLI1 levels and survival, and shown that GLI1
silencing in ER negative breast cancer markedly reduces survival
(Zhao et al, 2009; Xu et al, 2010) and invasiveness (Kameda et al,
2009; Souzaki et al, 2011). Although both SUM149 and SUM190 are
ER- we only observed high GLI1 levels in SUM149. Presumably
additional factors contribute to the elevated GLI1 status in the
triple-negative Basal B-like SUM149 cells.
In addition, we were interested in developing high-content
imaging assays to not only glean more quantitative information
from the motility wound-healing assay, but to also extract other
critical parameters defining migration behaviour. The advantages
of the wound-healing assay are that it can be miniaturised and is
compatible with microscopy, making it adaptable to high-
throughput imaging. Such a HCAM system allows the analysis of
both population and single-cell data on a heterogeneous popula-
tion of cells and can potentially link phenotypic variability to
genetic differences (Quaranta et al, 2009). To obtain a more
quantitative assessment and further assess the role of GLI1 in the
migratory phenotype, we tagged SUM149 cells with H2B-GFP to
fluorescently label nuclei of living cells and using a high-content
live-cell fluorescence-based imaging system demonstrated that we
can track not only cell migration but additional parameters of
motility such as linearity of movement and integrated distance
travelled. Both average linearity and distance travelled were
reduced in SUM149 cells with GLI1 silenced. Further, our proof-
of-principle study described here allowed us to distinguish
differences in phenotype. GLI1 knockdown cells continue to move
although with much reduced linearity and distance travelled.
Indeed, the mean velocity between controls and GLI1 knockdown
did not change significantly. In comparison, we observed that dyes
such as MitoTracker Red affect the motility phenotype of SUM149
cells with the result that these cells have no motility. We expect this
type of multi-parameter analysis of cell migration after H2B-GFP
tagging to be generally applicable to many cell types to assess
effects on migration.
Our data suggest a Hh-ligand-independent/SMO-independent
mechanism of GLI1 gene overexpression operates in SUM149 and
rSUM149 cells although we cannot rule out a role for other
Hh-pathway components such as changes in SUFU (suppressor of
FUSED) in activating GLI1. A number of other pathways have
been reported to influence the cellular levels of GLI1 (Riobo
et al, 2006b) including TGF-b (Dennler et al, 2007), PI3K/AKT
(Riobo et al, 2006a), Ras/Mek (Stecca et al, 2007), and a recently
described novel GLI1-CDK2-dependent mechanism (Rizvi et al,
2010). Further analyses using a range of pharmacological
inhibitors to assess the role of other pathways in activating
GLI1 and the phenotype of SUM149 and rSUM149 cells are
planned in future studies. The understanding of those pathways
converging on GLI in SUM149 will guide drug development
strategies. It has been suggested that due to the complexity of
signalling inputs into GLI (Ruiz et al, 2007; Stecca and Ruiz, 2010),
targeting GLI in cancers may provide a more comprehensive
strategy for treating both canonical and non-canonical Hh-
pathway-dependent cancers. Further, it has been proposed that
GLI-directed compounds that block growth in one cell type may be
ineffective in others (Hyman et al, 2009) and indeed, it may be
necessary to directly screen specific cancer cell lines for
compounds that specifically inhibit GLI1 expression in a particular
cellular context.
Few studies have examined the molecular biology of IBC due to
its relative low incidence; however, due to its high aggressiveness,
mortality rate, and resistance to chemotherapeutic drugs
(Rouesse et al, 1986), additional investigations are warranted. In
light of our observation that GLI1 has a role in proliferation,
survival and migration of a subset of IBC cells, we propose that
direct targeting of GLI1 transcription may be a novel and
promising strategy for targeting triple-negative/Basal B IBC
modelled by SUM149 cells.
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